Skip to main content
SpringerLink
Log in

Vaccines and Vaccine Policy for Universal Healthcare

  • Chapter
  • First Online:
Universalising Healthcare in India

  • 194 Accesses

Abstract

Vaccines are among the cost-effective preventive tools of disease management in primary healthcare. Vaccines are useful for mass immunisation, especially against diseases that are spread uniformly in populations and when their use is balanced with other public health measures.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • American Academy of Pediatrics (AAP). (1999, May). Recommendations of the advisory committee on immunisation practices (ACIP). Pediatrics, 103(5), 1064–77.

    Google Scholar 

  • Anonymous. (1985, August). Just beginning: A new era of vaccines. Chemical Weekly, 137(9), 58.

    Google Scholar 

  • Arora, R., & Puliyel, J. M. (2005). Economic evaluation tailored to promote vaccine uptake: How third world consumers can respond. Expert Review of Pharmacoeconomics and Outcomes Research, 5(5), 515–516.

    Article  Google Scholar 

  • Bajpai, V., & Saraya, A. (2012a, January–March). Agenda setting in vaccine policy and social relevance of the emerging vaccine technologies from public health perspective. Part 2. International Journal of Medicine and Public Health, 2(1), 16–25.

    Google Scholar 

  • Bajpai, V., & Saraya, A. (2012b, August 21). Understanding the syndrome of techno-centrism through the epidemiology of vaccines as preventive tools. Indian Journal of Public Health, 56(2), 133–139.

    Google Scholar 

  • Balgescu, M., & Young, J. (2005). Partnerships and accountability: current thinking and approaches among agencies supporting Civil Society organisations. Overseas Development Institute.

    Google Scholar 

  • Bar-On, E. S., Goldberg, E., Fraser, A., Vidal, L., Hellmann, S., & Leibovici, L. (2009, July 8). Combined DTP–HBV–HiB vaccine versus separately administered DTP–HBV and HIB vaccines for primary prevention of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenzae B (HIB). In Cochrane Acute Respiratory Infections Group (Ed.), Cochrane Database of Systematic Reviews (pp. 1–57). Wiley.

    Google Scholar 

  • Beeching, N. J., Clarke, P. D., Kitchin, N., Pirmohamed, J., Veitch, K., & Weber, F. (2004, November 15). Comparison of two combined vaccines against Typhoid fever and Hepatitis A in healthy adults. Vaccine, 23(1), 29–35.

    Google Scholar 

  • Beri, R. S., Ojha, & Kant, R. (2012, November 6). Is Hib vaccination required at all in India? Indian Pediatrics, 39(11), 1067–1068.

    Google Scholar 

  • Bhadoria, V., Gobinath, A., Mitra, P., & Narayanan, M. (2012, September 15). Transforming India’s vaccine market. Prepared by Mckinsey and Company for Organisation of Pharmaceutical Producers of India (OPPI), Mumbai, pp. 1–33.

    Google Scholar 

  • Blumenthal, D., Causino, N., Campbell, E., & Louis, K. S. (1996, February 8). Relationships between academic institutions and industry in the life sciences: An industry survey. New England Journal of Medicine, 334(6), 368–373.

    Google Scholar 

  • Bruce, M. G., Shelley, L., Tammy, Z., Navarro, C., Case, C., Hemsley, C., Hennessy, T., Corriveau, A., Larke, B., Sobel, I., Lovgren, M., DeByle, C., Tsang, R., Parkinson, J. A., and the International Circumpolar Surveillance Hib Working Group. (2008, January). Epidemiology of Haemophilus influenza Serotype A, North American Arctic, 2000–2005. Emerging Infectious Diseases, 14(1), 48–55.

    Google Scholar 

  • Buse, K., & Walt, G. (2000, April). Global public–private partnerships part I: A new development in vaccines? Bulletin of the World Health Organisation, 78(4), 549–561.

    Google Scholar 

  • Buse, K. (2004). Governing public-private infectious disease partnerships. Brown Journal of World Affairs, X(2), 225–242.

    Google Scholar 

  • Buttery, J.P. FRACP; Riddell, A. MRCPCH; McVernon, J. (2005, April 13). Immunogenicity and safety of a combination pneumococcal-Meningococcal vaccine in infants: A randomised controlled study. Journal of the American Medical Association, 293(14), 1751–1758.

    Google Scholar 

  • Center for Disease Control and Prevention. (1999, July 30). Achievements in public health, 1900s–1999: Control of infectious diseases. Morbidity and Mortality Weekly Report (MMWR), 48(29), 621–629.

    Google Scholar 

  • Center for Disease Control and Prevention Press Release. (2004, September 20). CDC Funds studies for Tuberculosis Vaccine trials, Aeras Foundation helps prepare for vaccine clinical trials in India, Distributed by the Bureau of International Information Program. US Department of State. Accessed December 25, 2012. http://www.america.gov/st/washfile-english/2004/September/20040920155159lcnirellep2.230471e-02.html

  • Comenge, Y., & Girard, M. (2006, September 21). Multiple sclerosis and Hepatitis B vaccination: Adding the credibility of molecular biology to an unusual level of clinical and epidemiological evidence. Medical Hypothesis, 66(1), 84–86.

    Google Scholar 

  • Donald, A. B. (2007, January). Ethics in public health research: A research protocol to evaluate the effectiveness of public-private partnerships as a means to improve health and welfare systems worldwide.” American Journal of Public Health, 97(1), 19–25.

    Google Scholar 

  • Dutta, P., & Puliyel, J. M. (2010, June). NTAGI Recommendations Overlooked Crucial ICMR Data. Indian Pediatrics, 47(6), 542–543.

    Google Scholar 

  • Edwards, K.M., & Decker, M. D. (1997). Combination vaccines consisting of a cellular pertussis vaccines. Pediatric Infectious Diseases Journal, 16(Suppl. 4), S97–102.

    Google Scholar 

  • Food and Drug Administration (FDA). (1997, April). Guidance for industry for the evaluation of combination vaccines for preventable diseases: Production, testing and clinical studies. Docket No. 97N-0029. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research.

    Google Scholar 

  • Frew, S. E., Rahim, R., Stephen, S. M., Monali, R., Abdallah, D. S., & Singer Peter, A. (2007). India’s health biotech sector at a crossroads. Nature Biotechnology, 25(4), 403–417.

    Google Scholar 

  • Gavi, The Vaccine Alliance. (2016). Keeping Children Healthy: The Vaccine Alliance Progress Report 2015.” (1–100). Geneva: Gavi Publication. Accessed 6 March, 2018. http://gaviprogressreport.org/2015/.

  • Girard, M. (2005, February). Auto-immune hazards of Hepatitis B vaccine. Autoimmunity Reviews, 4(2), 96–100.

    Google Scholar 

  • Government of India (GoI). (2011). Report of the working group on disease burden for the twelfth five year plan. WG 3(1): Communicable Diseases. Planning Commission.

    Google Scholar 

  • Guzman, T. A. (2016). Big pharma and big profits: The multibillion dollar vaccine market. Silent Crow News, 26, 2016.

    Google Scholar 

  • Ministry of Health and Family Welfare (MoHFW), Government of India (GoI). (2011). National Vaccine Policy. MOHFW.

    Google Scholar 

  • MoHFW. Javed Chowdhury Committee Report. (2010). Final Report of the Committee Set up to Determine the Reasons for the Suspension of the Manufacturing License of CRI Kasauli, PII Coonoor, and BCGVL Guindy, and to Draw the Road-map for the Revival of the Three Units (1–74).

    Google Scholar 

  • Greenberg, P., Wong, V. K., Partridge, S. B., Chang Swei-Ju, J., Jing, B. J., Howe, & Ward, J. I. (2000). Immunogenecity of a Hemophilus Influenza Type B–Tetanus Toxoid Conjugate Vaccine when Mixed with Diphtheria– Tetanus–Acellular Pertussis–Hepatitis B Combination Vaccine. Pediatric Infectious Disease Journal, 19(12), 1135–1140.

    Google Scholar 

  • Harrison, P. H. (1999). A new model for collaboration: The alliance for microbicide development. International Journal of Gynecology and Obstetrics, 67(Suppl. S2), S39–S53.

    Google Scholar 

  • Invasive Bacterial Infections Surveillance (IBIS) Group of the International Clinical Epidemiology Network. (2002). Are Haemophilus influenzae infections a significant problem in India? A prospective study and review. Clinical Infectious Diseases, 34(7), 949–957.

    Google Scholar 

  • Jesani, A., & Coutinho, L. (2007). AIDS vaccine trials in India: Ethical benchmarks and unanswered questions. Indian Journal of Medical Ethics, 4(1), 2–3.

    Google Scholar 

  • Jones, I.G., Tyrrell, H., Hill, A., Horobin, J.M., & Taylor, B. (1998). Randomised control-led trial of combined diphtheria, Tetanus, whole-cell Pertussis vaccine administered in the same syringe and separately with Haemophilus Influenzae Type B vaccine at two, three and four months of age. Vaccine, 16(1), 109–113.

    Google Scholar 

  • Kalies, H., Verstraeten, T., Grote, V., Meyer, N., Siedler, A., Schmitt, H., Breuer, T., Moulton, L. H., & von Kries, R. (2004). Four-and a half year follow up of the effectiveness of Diphtheria–Tetanus Toxoid–Acelluar Pertussis/Hemophiplus influenza type B and Diphtheria–Tetanus Toxoid– Acellular Pertussis–Inactivated Poliovirus/H Influenza Type B combination vaccine in Germany. Pediatric Infectious Disease Journal, 23(10), 944–950.

    Google Scholar 

  • Klein, N. P., Fireman, B., Katherine Yih, W., Lewis, E., Kulldorff, M., Ray, P., Baxter, R., Hambidge, S., Nordin, J., Naleway, A., Belongia, E. A., Lieu, T., Baggs, J., & Weintraub, E. (2010). Measles-Mumps-Rubella-Varicella combination vaccine and the risk of Febrile Seizures. Pediatrics, 126(1), e1–e8.

    Google Scholar 

  • Lipsitch, M. (1999). Bacterial vaccines and Serotype replacement: Lessons from Haemophilus Influenza and prospects for streptococcus pneumonia. Emerging Infectious Diseases, 5(3), 336–345.

    Google Scholar 

  • Lone, Z., & Puliyel, J.M. (2010). Introducing Pentavalent vaccine in the EPI in India: A counsel for caution. Indian Journal of Medical Research, 132(1), 1–3.

    Google Scholar 

  • Mackenbach, J. P., Stirbu, I., Roskam, A. J., Schaap, M. M., Menvielle, G., Leinsalu, M., & Kunst, A. E., European Union working group on socioeconomic inequalities in health 2008. European Union Working Group on Socioeconomic Inequalities in Health: Socioeconomic Inequalities in Health in 22 European Countries. New England Journal of Medicine, 358(23), 2468–2481.

    Google Scholar 

  • Madhavi, Y. (2003). The manufacture of consent? Hepatitis B vaccination. Economic and Political Weekly, 38(24), 2417–2424.

    Google Scholar 

  • Madhavi, Y. (2005). Vaccine policy in India. PLOS Medicine Weekly, 2(5), e127: 387–391.

    Google Scholar 

  • Madhavi, Y. (2006). New combination vaccines: Backdoor entry into India’s universal immunisation programme?.” Current Science, 90(11), 1465–1469.

    Google Scholar 

  • Madhavi, Y. (2008). Vaccine PSUs: Chronicle of an attenuation wilfully caused. Medico Friends Circle Bulletin (MFC), 329, 1–7.

    Google Scholar 

  • Madhavi, Y. (2009a, September 23). Home-grown Vaccines are Crucial for Public Health. Opinions, scidev.net. Accessed December 25, 2012. http://www.scidev.net/en/opinions/home-grown-vaccines-are-crucial-for-public-health.html.

  • Madhavi, Y. (2009b, November). Meeting local Needs in Global Times: The Case of Universal Vaccines in India. Journal of Health Studies II, No., 2, 81–105.

    Google Scholar 

  • Madhavi, Y., et al. (2010). Evidence-based national vaccine policy. Indian Journal of Medical Research, 131(5), 617–628.

    Google Scholar 

  • Madhavi, Y., & Raghuram, N. (2010a, May 17). Crisis of Speculation: Donors Should Fund Only Locally Proven Vaccine Needs and Local Capacity Building. British Medical Journal, 340, c2576. Accessed March 6, 2018 http://www.bmj.com/content/340/bmj.c2576/rapid-responses

  • Madhavi, Y., & Raghuram, N. (2010b). Pentavalent and other new combination vaccines: Solutions in search of problems. Indian Journal of Medical Research, 132(4), 456–457.

    Google Scholar 

  • Madhavi, Y., & Raghuram, N. (2012). National vaccine policy in the era of vaccines seeking diseases and governments seeking public private partnerships. Current Science, 102(4), 57–58.

    Google Scholar 

  • Minz, S., Balraj, V., Lalitha, M.K., Murali, N., Cherian, T., Manoharan, G., Kadirvan, S., Joseph, A., & Steinhoff, M.C. (2008, July). Incidence of Haemophilus Influenzae Type B Meningitis in India. Indian Journal of Medical Research, 128(1), 57–64.

    Google Scholar 

  • Muhlemann, K., Balz, M., Aebi, S., & Schopfer, K. (1996, March). Molecular characteristics of Haemophilus influenza causing invasive disease during the period of vaccination in Switzerland: Analysis of strains isolated between 1986 and 1993. Journal of Clinical Microbiology, 34(3), 560–563.

    Google Scholar 

  • Muraskin, W. (2002). The last years of the CVI and the birth of the GAVI. In Reich, M. R. (Ed.), Public private partnerships for public health. Series on Population and International Health. Harvard Centre for Population and Development Studies.

    Google Scholar 

  • Nundy, S., & Gulhati, C.M. (2005, April 21). A new colonialism? Conducting clinical trials in India. The New England Journal of Medicine, 352(16), 1633–1636.

    Google Scholar 

  • Parliamentary Standing Committee on Health and Family Welfare. (2009). 34th Parliamentary Standing Committee on Health and Family Welfare. New Delhi: Parliament of India, Rajya Sabha, Government of India.

    Google Scholar 

  • Parliamentary Standing Committee on Health and Family Welfare. (2009b). 38th Parliamentary Standing Committee on Health and Family Welfare. Parliament of India, Rajya Sabha, Government of India.

    Google Scholar 

  • Parliamentary Standing Committee on Health and Family Welfare. (2010). 43rd Parliamentary Standing Committee on Health and Family Welfare. Parliament of India, Rajya Sabha, Government of India.

    Google Scholar 

  • Parliamentary Standing Committee on Health and Family Welfare. (2011). 52nd Parliamentary Standing Committee on Health and Family Welfare. Parliament of India, Rajya Sabha, Government of India.

    Google Scholar 

  • Phadke, A., and A. Kale. 2000. “Epidemiology and Ethics in the Hepatitis B Vaccine.” Indian Journal of Medical Ethics 8, No. 2 (April-June) C7: 8–10.

    Google Scholar 

  • Pichichero, M. E., Thomas, L., David, I.B., Philip, H., Edward, C., Emmanuel, V., Carlton, M., & Robert, S. D. (1997). vaccine Antigen Interactions after a Combination Diphtheria—Tetanus Toxoid Acellular Pertussis/Purified Capsular Polysaccharide of Hemophilus Influenzae type B Tetanus Toxoid Vaccine in Two, Four, and Six-Month-Old Infants. Pediatric Infectious Diseases Journal, 16(9), 863–870.

    Google Scholar 

  • Puliyel, J. (2011). Vaccine policy and advance market commitment. Economic and Political Weekly, 46, 44–45.

    Google Scholar 

  • Puliyel, J. M., Agarwal, K. S., & Abass, F. A. (2001). Natural immunity to Haemophilus influenzae in infancy in Indian children. Vaccine, 19(32), 4592–4594.

    Google Scholar 

  • Puliyel, J. M., Mathew, J. L., & Priya, R. (2010). Incomplete Reporting of Research in Press Releases: et tu, WHO?. Indian Journal of Medical Research, 131(4), 588–589.

    Google Scholar 

  • Puliyel, J. M., GAVI (Global Alliance for Vaccines and Immunisation), and WHO. (2010). Demanding accountability. British Medical Journal, 341(7767), c4081–4266.

    Google Scholar 

  • Puliyel, J. M., & Mathew, J. L. (2012). Should India launch a national immunisation programme against Rotavirus Vaccine?. BMJ , 345:, e7832. Accessed December 3, 2012. http://www.bmj.com/content/345/bmj.e7832.pdfpercent2Bhtml

  • Ramachandran, R. (2008). Vaccine worries. Frontline, 25(7), 4–27.

    Google Scholar 

  • Reich, M. R. (2000). The global drug gap. Science, 287(5460), 1979–1981.

    Google Scholar 

  • Reich, M. R. (2002). Introduction: Public Private Partnerships for Public Health. In M. R. Reich (Ed.), Public Private Partnerships for Public Health,. Harvard Series on Population and International Health. Harvard Centre for Population and Development Studies.

    Google Scholar 

  • Sarojini, N. B., Sandhya, S., Madhavi, Y., Srinivasan, S., & Anjali, S. (2010). The HPV vaccine: Science, ethics and regulation.” Economic and Political Weekly, 45(48), 27–34.

    Google Scholar 

  • Sathyamala, C. (2006). Public Health Foundation of India: Redefining Public Health? Economic and Political Weekly, 41(30), 3280–3284.

    Google Scholar 

  • Sengupta, A., Anjali Shenoy, N.B. Sarojini, and Y. Madhavi. 2011. “Human Papilloma Vaccine Trials in India.” The Lancet, 377, 719.

    Google Scholar 

  • Sinha, K. (2012, February 11). Public investment board gives nod to set up vaccine park near Chennai. The Times of India. http://timesofindia.indiatimes.com/india/Public-Investment-Board-gives-nod-to-set-up-vaccine-park-near-Chennai/articleshow/11843445.cms?prtpage=1&TOI_browsernotification=true

  • Smith, R. (2000). Vaccines and medicines for the world’s poorest: Public–private partnerships seem to be essential. British Medical Journal, 320, 952–953.

    Google Scholar 

  • Srinivas, S. (2004). Demand Policy Instruments for R&D: Procurement, Technical Standards and the Case of Indian Vaccines (BCSIA Discussion Paper 2004–09), December. Kennedy School of Government, Harvard University.

    Google Scholar 

  • Times News Network (TNN). (2016, October 6). City to Get Vaccine Making Medical Park. The Times of India. http://timesofindia.indiatimes.com/city/chennai/City-to-get-vaccine-making-medical-park/articleshow/54706464.cms

  • United Nations Development Programme (UNDP). (1998). The Global Sustainable Development Facility (Internal Document).UNDP.

    Google Scholar 

  • Vesikari, T., Ohrling, A., Baer, M., Delem, A., Bogaerts, H., & Andre, F. E. (1991). Evaluation of Live Attenuated Varicella Vaccine (Oka-RIT Strain) and Combined Varicella and MMR Vaccination in 13–17 month-old Children. Acta Paediatrica Scandinavica, 80(11), 1051–1057.

    Google Scholar 

  • White, J., Stinson, D., Staehle, B., Cho, I., Matthews, H., Ngai, A., Keller, P., Eiden, J., Kuter, B., The MMRV Vaccine Study Group. (1997, May). Measles, Mumps, Rubella, and Varicella Combination Vaccine: Safety and immunogenecity alone and in combination with other vaccines given to children. Clinical Infectious Diseases, 24(5), 925–931.

    Google Scholar 

  • Wilson, P., & Jones, A. (2010, April). Giving developing countries the best shot. An Overview of Vaccine Access and R&D.” Oxfam–MSF Report. Geneva, Switzerland.

    Google Scholar 

  • World Bank. (1998, May 20). Partnerships for development: Proposed actions for the World Bank (Discussion Paper, Partnership Group). World Bank. Accessed March 7, 2018. http://documents.worldbank.org/curated/en/789141468153858137/pdf/516050WP0Dev0i10Box342046B01PUBLIC1.pdf

  • World Health Organisation (WHO). (1999, June 24). WHO guidelines on collaboration and partnerships with commercial enterprises (draft discussion document). World Health Organisation.

    Google Scholar 

  • World Health Organisation (WHO). (2012, June). Information sheet observed rate of vaccine reactions Varicella zoster Virus Vaccine. June 2012. (Global Vaccine Safety, Immunisation, Vaccines and Biologicals). WHO. 1–4. Accessed May 2, 2013. http://www.who.int/vaccine_safety/initiative/tools/Varicella_Zoster_Vaccine_rates_information_sheet.pdf

  • WHO. (2005, January 28). Pertussis Vaccines, WHO Position Paper. Weekly Epidemiological Record, 80(4), 31–39. http://www.who.int/immunisation/topics/wer8004pertussis_Jan_2005.pdf

Download references

Author information

Authors and Affiliations

  1. National Institute of Science, Technology and Development Studies, New Delhi, India

    Y. Madhavi

Authors
  1. Y. Madhavi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Council for Social Development, New Delhi, Delhi, India

    Imrana Qadeer

  2. Council for Social Development, New Delhi, Delhi, India

    K. B. Saxena

  3. School of Indian Legal Thought, Mahatma Gandhi University, Kottayam, Kerala, India

    P. M. Arathi

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s)

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Madhavi, Y. (2021). Vaccines and Vaccine Policy for Universal Healthcare. In: Qadeer, I., Saxena, K.B., Arathi, P.M. (eds) Universalising Healthcare in India. Springer, Singapore. https://doi.org/10.1007/978-981-16-5872-3_15

Download citation

Publish with us

Policies and ethics

Search

Navigation